Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
B-lymphocyte antigen CD20 (CD20)
- Target
- CD20
- Molecular classification
- Membrane protein, Tetraspan protein, Receptor
01
Overview
CD20, also known as MS4A1, is a non-glycosylated phosphoprotein expressed on the surface of B lymphocytes from the pre-B cell stage through mature B cells. It is a key regulator of B-cell development, differentiation, and BCR signaling. As a therapeutic target, it is engaged by monoclonal antibodies like rituximab to deplete B cells in B-cell malignancies and autoimmune diseases. CD20 does not internalize or shed upon antibody binding, making it an effective target for complement-mediated cytotoxicity.
- Other names
- MS4A1
02
Mechanism of action
Antibody binding induces clustering/capping of CD20, promoting complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), leading to B-cell depletion.
03
Biological functions
B-cell developmentB-cell differentiationB-cell receptor signalingRegulation of B-cell activationHumoral immune responseMaintenance of B-cell resting state
04
Disease associations
Non-Hodgkin lymphomaChronic lymphocytic leukemiaRheumatoid arthritisAutoimmune disorders
05
Safety considerations
Infusion reactionsTumor lysis syndromeProgressive multifocal leukoencephalopathy (PML)Hepatitis B virus reactivationHypogammaglobulinemiaIncreased risk of infection
06
Interacting drugs
Rituximab
2 more in the full profile.
07
Biomarkers
CD20 expression level on B cells (for patient selection)B-cell count (for monitoring treatment efficacy)
Beyond the preview
Go deeper on B-lymphocyte antigen CD20 (CD20).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B-lymphocyte antigen CD20 (CD20).